financetom
Market
financetom
/
Market
/
China chipmaker CXMT's shares surge 470% in Shangai trading debut
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
China chipmaker CXMT's shares surge 470% in Shangai trading debut
Jul 26, 2026 7:06 PM

By Yantoultra Ngui and Samuel Shen

SINGAPORE/SHANGHAI, July 27 (Reuters) - Shares of CXMT Corp surged nearly 470% at their Shanghai debut on Monday after Asia's biggest IPO this year, catapulting the chipmaker to the top of China's stock market by valuation despite a recent selloff in global tech stocks.

The stock began trading at 49.50 yuan compared to their sale price of 8.66 yuan per share. The rally in the first few minutes lifted CXMT's market capitalisation to 3.3 trillion yuan ($487.31 billion), sharply up from $85.5 billion during the IPO process.

The explosive debut makes CXMT the most valuable company listed in China, overtaking Industrial and Commercial Bank of China (ICBC), the market's previous heavyweight.

The debut will give investors a gauge of how much they are willing to pay for a marquee Chinese chip firm, as local markets navigate volatility following an AI-led selloff, and money rotates between high-growth technology names and safer sectors.

CXMT, formally ChangXin Memory Technologies, raised 57.92 billion yuan ($8.6 billion) and the proceeds could rise to 66.61 billion yuan if an over-allotment option is fully used.

At the IPO price, CXMT was valued at about 579 billion yuan ($85.5 billion) before the possible exercise of the over-allotment option, making it one of China's largest listed semiconductor companies.

Only 6.73% of CXMT's enlarged share capital will be freely tradable at listing, as most shares are locked up. The small initial float could magnify price swings and attract strong turnover.

HSBC Qianhai Securities said in a note last week that the offering could drain liquidity from the wider Chinese market before and on its debut, though past technology listings suggested a rebound could follow the next trading day.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nvidia Earnings in Focus as US Equity Futures Post Narrow Gains Pre-Bell
Nvidia Earnings in Focus as US Equity Futures Post Narrow Gains Pre-Bell
Nov 21, 2024
08:50 AM EST, 11/21/2024 (MT Newswires) -- US equity futures were cautiously higher ahead of Thursday's opening bell as traders digested earnings and guidance from artificial intelligence chipmaker Nvidia ( NVDA ) . Dow Jones Industrial Average futures rose 0.4%, S&P 500 futures gained 0.4%, and Nasdaq futures were up 0.3%. Nvidia ( NVDA ) reported late Wednesday fiscal Q3...
Sector Update: Tech
Sector Update: Tech
Nov 21, 2024
08:45 AM EST, 11/21/2024 (MT Newswires) -- Technology stocks were edging higher premarket Thursday as the Technology Select Sector SPDR Fund (XLK) was up 0.7% and the SPDR S&P Semiconductor ETF (XSD) marginally advanced. Snowflake (SNOW) shares rose past 24% after the company reported fiscal Q3 earnings and sales above analyst expectations. ...
US STOCKS-Wall St set for higher open after jobless claims data, Nvidia results
US STOCKS-Wall St set for higher open after jobless claims data, Nvidia results
Nov 21, 2024
(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window.) * Snowflake jumps after raising annual product revenue forecast * Deere shares up after Q4 profit beats estimates * Crypto stocks gain as bitcoin prices near $100,000 * Weekly jobless claims stand at 213,000 * Futures: Dow up 0.45%, S&P...
Sector Update: Health Care
Sector Update: Health Care
Nov 21, 2024
08:52 AM EST, 11/21/2024 (MT Newswires) -- Health care stocks rose in pre-bell hours Thursday with the Health Care Select Sector SPDR Fund (XLV) 0.1% higher and the iShares Biotechnology ETF (IBB) up 0.3% recently. Zymeworks ( ZYME ) and Jazz Pharmaceuticals ( JAZZ ) said they have received accelerated approval for Ziihera from the US Food and Drug Administration...
Copyright 2023-2026 - www.financetom.com All Rights Reserved